ALL
Conference Coverage
Immunotherapy drug boosts survival in newly diagnosed ALL
First-line treatment with expensive medication should become standard, researcher says.
Conference Coverage
‘Clear answer’: ALL study defies conventional wisdom
Research on pediatric blood cancers found that high-dose methotrexate does not help cut the risk for central nervous system relapse.
Conference Coverage
ASH 2022: New clinical data challenge long-held assumptions
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...
From the Journals
Novel co-admin of CAR T cells achieves 99% remission in leukemia
“We do believe [this approach] will become standard of care.”
Feature
Worldwide trial seeks to revolutionize pediatric leukemia care
Leukemia & Lymphoma Society project offers free genomic screening, plus access to subtrials.
From the Journals
CAR T-cell therapy neurotoxicity linked to NfL elevations
Even prior to CAR T-cell therapy, patients developing related neurotoxic complications show elevated markers of neuronal injury.
News
First drug therapy approved for childhood GVHD
FDA greenlights ibrutinib for child blood cancer patients with chronic graft-versus-host disease.
Feature
Young children with leukemia are outliving teens
Two new studies spotlight age disparities that continue to plague blood cancer care.
Conference Coverage
Many die waiting for `last-chance’ therapy
Blood cancer patients, especially those with myeloma, face hospice and death while awaiting CAR T-cell therapy.
Feature
CAR T-cell therapy turns 10 and finally earns the word ‘cure’
“We have a couple dozen patients who are 5, 6, 7, 9 years out or more without further therapy. That feels like a cure to me.”
Feature
Drug shortages plague hematology, but preparedness helps
The plight of desperate patients is getting attention – and some remedies.